The Cigna unit positioned the initiative as a cheaper alternative to cash-pay programs. Wegovy maker Novo Nordisk and Zepbound ... numerous forays into the GLP-1 space. Last year, the company ...

Cigna’s Evernorth has reached new deals with manufacturers Eli Lilly and Novo Nordisk to cap patients ... costs at $200 per month and reduces GLP-1 prices for their plan sponsor.

Novo Nordisk NVO and Viking Therapeutics VKTX have emerged as notable players in the obesity space. A market leader in the GLP-1 space, Novo Nordisk markets its semaglutide drugs under brand names ...

Novo Nordisk NVO and Viking Therapeutics VKTX have emerged as notable players in the obesity space. A market leader in the GLP-1 space, Novo Nordisk markets its semaglutide drugs under brand names ...

This pricing suggests strong market confidence in Novo Nordisk's ability to capitalize on the expanding GLP-1 market and meet the increasing demand for anti-obesity medications. Want deeper insights?

The percentage of adults prescribed a GLP-1 drug like Wegovy or Zepbound jumped almost sevenfold over the past five years, ...

Hims & Hers Health is betting that the cash-pay market for weight-loss drugs will drive up customer demand although some ...

The percentage of overweight or obese adults prescribed GLP-1s jumped by almost 587% between 2019 and 2024, according to a ...

Only half of health insurer Cigna's clients currently cover the popular GLP-1 weight loss ... drug makers Ely Lilly and Novo Nordisk which it said will bring prices down for employers and their ...

Investing.com -- Cigna ... for GLP-1 weight loss medications at $200 per month, in a move analysts say is more favorable for Eli Lilly (NYSE:LLY) than rival models. Announced late Wednesday, the ...